-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MW2AA1Ly3UrljrgL/RlXBxsLv2ZByJwc0i00EalZncI9QER2nvtzQE7+Wv5Z2ad/ EJQX47enuxsopWD4x2uAcw== 0001218816-03-000002.txt : 20031002 0001218816-03-000002.hdr.sgml : 20031002 20031002141701 ACCESSION NUMBER: 0001218816-03-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030930 FILED AS OF DATE: 20031002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAPLAN CARL E CENTRAL INDEX KEY: 0001218816 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 03923522 MAIL ADDRESS: STREET 1: C/O FULBRIGHT & JAWORSKI LLP STREET 2: 666 FIFTH AVE CITY: NEW YORK STATE: NY ZIP: 10103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 4 1 edgar.xml PRIMARY DOCUMENT X0201 42003-09-30 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001218816 KAPLAN CARL E C/O FULBRIGHT & JAWORSKI LLP 666 FIFTH AVENUE NEW YORK NY 10103 1000Common stock, $.01 par value per share2003-09-302003-09-304A04954.14A9746DOptions to purchase common stock, $.01 par value pe share4.142003-09-302003-09-304A050004.14A2004-09-30201 3-09-30Common stock, $.01 par value per share50009746DThese shares were granted pursuant to the Company's Stock Compensation Plan for Outside Directors, which provides for the grant to non-employee directors of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter equal to $2,500, until he is no longer an Outside Director. On September 30, 2003, the fair market value of the Common Stock, based on the c losing price, was $4.14.These options will become fully vested and immediately exercisable on 9/30/2004./s/ Carl Kaplan2003-10-02 -----END PRIVACY-ENHANCED MESSAGE-----